• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小RNA 29a和微小RNA 335在乳腺癌治疗中的临床作用:它们与基质金属蛋白酶2蛋白水平的相关性。

Clinical role of MiRNA 29a and MiRNA 335 on breast cancer management: their relevance to MMP2 protein level.

作者信息

Ali Ahmed Elham, Abd El-Basit Sohir A, Mohamed Mona A, Swellam Menha

机构信息

Zoology Department, Faculty of Science (Girls), Al-Azhar University, Cairo, Egypt.

Biochemistry Division, Chemistry Department, Faculty of Science (Girls), Al-Azhar University, Cairo, Egypt.

出版信息

Arch Physiol Biochem. 2022 Aug;128(4):1058-1065. doi: 10.1080/13813455.2020.1749085. Epub 2020 Apr 8.

DOI:10.1080/13813455.2020.1749085
PMID:32267166
Abstract

BACKGROUND

Circulating miRNAs are novel biomarkers, authors aimed to investigate the expression level of miR-29a and miR-335 and their relevance to CEA, CA15.3, and matrix metalloproteinase-2 (MMP2).

MATERIALS AND METHODS

Breast cancer (BC) patients ( = 44), benign breast lesion patients ( = 25), and healthy individuals ( = 19) were enrolled for detection of miRNA expression levels, MMP2 and biochemical markers using quantitative polymerase chain reaction (PCR) and ELISA, respectively.

RESULTS

Expression of miR-29a and miR-335 were significantly decreased in breast patients as compared to healthy individuals, while biochemical markers were high in BC patients as compared to the other two groups. The diagnostic efficacy for miR-29a, miR-335, and MMP2 were superior to both CEA and CA 15.3 for early detection of BC patients.

CONCLUSIONS

Detection of the miR-29a and miR335 expression levels in serum samples are significant promising biomarkers for BC diagnosis.

摘要

背景

循环miRNA是新型生物标志物,作者旨在研究miR-29a和miR-335的表达水平及其与癌胚抗原(CEA)、糖类抗原15.3(CA15.3)和基质金属蛋白酶-2(MMP2)的相关性。

材料与方法

纳入乳腺癌(BC)患者(n = 44)、乳腺良性病变患者(n = 25)和健康个体(n = 19),分别采用定量聚合酶链反应(PCR)和酶联免疫吸附测定(ELISA)检测miRNA表达水平、MMP2及生化标志物。

结果

与健康个体相比,乳腺癌患者中miR-29a和miR-335的表达显著降低,而与其他两组相比,乳腺癌患者的生化标志物水平较高。miR-29a、miR-335和MMP2对乳腺癌患者早期检测的诊断效能优于CEA和CA15.3。

结论

检测血清样本中miR-29a和miR-335的表达水平是乳腺癌诊断中极具前景的生物标志物。

相似文献

1
Clinical role of MiRNA 29a and MiRNA 335 on breast cancer management: their relevance to MMP2 protein level.微小RNA 29a和微小RNA 335在乳腺癌治疗中的临床作用:它们与基质金属蛋白酶2蛋白水平的相关性。
Arch Physiol Biochem. 2022 Aug;128(4):1058-1065. doi: 10.1080/13813455.2020.1749085. Epub 2020 Apr 8.
2
Expression of MiR-335 and its target metalloproteinase genes: clinical significance in breast cancer.miR-335 及其靶基因金属蛋白酶的表达:在乳腺癌中的临床意义。
Arch Physiol Biochem. 2022 Jun;128(3):569-575. doi: 10.1080/13813455.2019.1703004. Epub 2020 Jan 10.
3
Assessment of serum microRNA-21 and miRNA-205 as diagnostic markers for stage I and II breast cancer in Indian population.评估血清微小RNA-21和微小RNA-205作为印度人群I期和II期乳腺癌诊断标志物的价值。
Indian J Cancer. 2024 Apr 1;61(2):290-298. doi: 10.4103/ijc.IJC_187_20. Epub 2023 Jul 17.
4
Decreased serum miR-181a is a potential new tool for breast cancer screening.血清 miR-181a 降低可作为乳腺癌筛查的潜在新工具。
Int J Mol Med. 2012 Sep;30(3):680-6. doi: 10.3892/ijmm.2012.1021. Epub 2012 Jun 11.
5
Clinical significance of blood-based miRNAs as diagnostic and prognostic nucleic acid markers in breast cancer: Comparative to conventional tumor markers.基于血液的 miRNA 作为乳腺癌诊断和预后核酸标志物的临床意义:与传统肿瘤标志物的比较。
J Cell Biochem. 2019 Aug;120(8):12321-12330. doi: 10.1002/jcb.28496. Epub 2019 Mar 1.
6
Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.血清微小RNA-195在乳腺癌中表达下调:一种潜在的乳腺癌诊断标志物。
Mol Biol Rep. 2014 Sep;41(9):5913-22. doi: 10.1007/s11033-014-3466-1. Epub 2014 Aug 8.
7
The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.sICAM-1 在鉴别良、恶性乳腺病变中的临床意义。
Ann Clin Lab Sci. 2020 Sep;50(5):650-656.
8
microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers.III 期结直肠癌的 microRNA 表达谱:循环 miR-18a 和 miR-29a 作为有前途的生物标志物。
Oncol Rep. 2013 Jul;30(1):320-6. doi: 10.3892/or.2013.2475. Epub 2013 May 15.
9
Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study.新型循环微小RNA特征作为雌激素受体阳性早期乳腺癌潜在的非侵入性多标志物检测:一项病例对照研究
Mol Oncol. 2014 Jul;8(5):874-83. doi: 10.1016/j.molonc.2014.03.002. Epub 2014 Mar 16.
10
Role of some circulating MiRNAs on breast cancer diagnosis.一些循环 miRNA 在乳腺癌诊断中的作用。
Arch Physiol Biochem. 2019 Dec;125(5):456-464. doi: 10.1080/13813455.2018.1482355. Epub 2018 Jun 20.

引用本文的文献

1
The assessment of breast cancer biomarkers in diagnosis, prognosis and treatment monitoring: integrated analysis.乳腺癌生物标志物在诊断、预后及治疗监测中的评估:综合分析
J Cancer Res Clin Oncol. 2025 Aug 22;151(8):233. doi: 10.1007/s00432-025-06271-1.
2
Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma.某些循环微RNA作为胶质母细胞瘤预后和治疗反应预测生物标志物的表达
Sci Rep. 2025 Jan 14;15(1):1933. doi: 10.1038/s41598-024-83800-x.
3
ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!
雌激素受体阴性乳腺癌与微小RNA:需要解读的内容远不止病理学家所能看到的!
Biomedicines. 2023 Aug 18;11(8):2300. doi: 10.3390/biomedicines11082300.
4
Short Activators and Repressors of RNA Toehold Switches.短 RNA 触发子和 RNA 分子信标阻遏物。
ACS Synth Biol. 2023 Mar 17;12(3):681-688. doi: 10.1021/acssynbio.2c00641. Epub 2023 Feb 21.
5
MiR-574-5p promotes cell proliferation by negatively regulating small C-terminal domain phosphatase 1 in esophageal squamous cell carcinoma.微小RNA-574-5p通过负向调控小C末端结构域磷酸酶1促进食管鳞状细胞癌的细胞增殖。
Iran J Basic Med Sci. 2022 Oct;25(10):1243-1250. doi: 10.22038/IJBMS.2022.65886.14492.
6
Potential utility of miRNAs for liquid biopsy in breast cancer.微小RNA在乳腺癌液体活检中的潜在应用价值
Front Oncol. 2022 Aug 4;12:940314. doi: 10.3389/fonc.2022.940314. eCollection 2022.
7
Circulating microRNAs as Reliable Tumor Biomarkers: Opportunities and Challenges Facing Clinical Application.循环 microRNAs 作为可靠的肿瘤生物标志物:临床应用面临的机遇与挑战。
J Pharmacol Exp Ther. 2023 Jan;384(1):35-51. doi: 10.1124/jpet.121.000896. Epub 2022 Jul 9.
8
Differential expression of microRNA between triple negative breast cancer patients of African American and European American descent.非裔美国人和欧洲裔美国人的三阴性乳腺癌患者之间 microRNA 的差异表达。
Biotech Histochem. 2022 Jan;97(1):1-10. doi: 10.1080/10520295.2021.2005147. Epub 2022 Jan 4.
9
miR-29a sensitizes the response of glioma cells to temozolomide by modulating the P53/MDM2 feedback loop.微小RNA-29a通过调节P53/MDM2反馈环使胶质瘤细胞对替莫唑胺敏感。
Cell Mol Biol Lett. 2021 May 27;26(1):21. doi: 10.1186/s11658-021-00266-9.
10
miRNA Regulatory Functions in Farm Animal Diseases, and Biomarker Potentials for Effective Therapies.miRNA 在农场动物疾病中的调控功能,以及有效治疗的生物标志物潜力。
Int J Mol Sci. 2021 Mar 17;22(6):3080. doi: 10.3390/ijms22063080.